Chiral switching, the practice of developing a single enantiomer from a previously approved racemic drug, has been a significant strategy […]

Developing a competitive edge in generic drug development is crucial for companies to gain a significant market share and dominate

To identify Key Starting Materials (KSMs) for Active Pharmaceutical Ingredients (APIs), pharmaceutical companies and regulatory bodies follow a systematic approach

The generic drug market has been significantly impacted by the COVID-19 pandemic, with both challenges and opportunities arising from the

In the high-stakes world of pharmaceuticals, generic drugs have become the unsung heroes of healthcare accessibility. These cost-effective alternatives to

In the high-stakes world of pharmaceutical innovation, drafting detailed drug patent claims is a critical process that can make or

In the ever-evolving world of pharmaceuticals, a controversial practice has emerged that’s causing quite a stir: biologic product hopping. But

Enantiomer Switching: A Pharmaceutical Strategy to Extend Drug Patents Enantiomer switching, also known as chiral switching, is a strategy employed

In the rapidly evolving landscape of biosimilars, intellectual property (IP) strategy is paramount. Biosimilar manufacturers face unique challenges, including navigating